Grade 3 hypophysitis induced by Adebrelimab (a PD-L1 inhibitor) in a patient with extensive-stage small cell lung cancer: a case report

The Body's Internal Security Guard and the Glitchy Alarm

Imagine your body is a high-tech fortress. Inside, there's a specialized security team called the immune system, whose job is to hunt down invaders like bacteria and viruses. But sometimes, this team gets too excited and starts attacking the fortress's own rooms, causing "friendly fire" damage. This is what happens in autoimmune diseases.

Now, imagine you have a very aggressive enemy inside the fortress: cancer. To fight it, doctors use a special kind of medicine called an immune checkpoint inhibitor. Think of these drugs as removing the "brakes" from the security team's car. Normally, the brakes (called checkpoints like PD-L1) stop the security team from getting too wild and hurting healthy tissue. By taking the brakes off, the medicine supercharges the immune system so it can finally crush the cancer.

However, there's a catch. When you remove the brakes, the security team might not just attack the cancer; they might also crash into the control room of the fortress. In this story, the "control room" is a tiny gland in the brain called the pituitary. It's the boss gland that tells other parts of the body how to make energy, handle stress, and grow. If the immune system attacks this boss gland, the whole body can start to feel very sick, confused, and exhausted. The big question for doctors is: How do we know if the medicine is working on the cancer or accidentally hurting the boss gland?

---

The Story of the Glitchy Boss Gland

This paper tells the story of a 60-year-old man who was fighting a tough type of lung cancer called "extensive-stage small cell lung cancer." He was doing well on a treatment plan that combined chemotherapy with a powerful immune-boosting drug called adebrelimab. This drug works by blocking the PD-L1 "brake" mentioned earlier, letting his immune system do its job.

For a while, everything went smoothly. He had six rounds of the combined treatment, and then he switched to just the immune drug (adebrelimab) to keep the cancer away. He received ten doses of this maintenance therapy. But then, about six months after starting the immune drug alone, things took a weird turn.

The Mystery Symptoms
Suddenly, the man started getting a persistent headache that got worse when he stood up. He felt dizzy, incredibly tired, and so weak he couldn't even walk to the bathroom on his own. He needed help with everything. At first, it looked like his cancer might have spread to his brain, or maybe the old chemotherapy was finally catching up to him. He even had a history of neck surgery, so doctors wondered if that was the problem.

The Detective Work
The medical team at The 903rd Hospital of the Joint Logistic Support Force started a deep investigation. They looked at his brain scans (MRI and CT) to see if there were tumors. They checked his spinal fluid for infection. They even looked for special antibodies that sometimes cause weird nerve problems.

• What they ruled out: No cancer in the brain. No infection. No signs that the chemotherapy was the culprit (since he hadn't had it in months). No signs of his neck surgery causing the issue.
• What they found: The real clue was in his blood. His body was screaming for help from his "stress hormone" (cortisol) and his "male hormone" (testosterone), but his pituitary gland wasn't sending the orders. His levels of ACTH (the messenger) and cortisol were dangerously low. His testosterone was also low. However, his thyroid (another gland) was still working fine.

Here is the tricky part: When they looked at his pituitary gland on the MRI, it looked perfectly normal. It wasn't swollen, and it didn't look like it had a tumor. Usually, when a gland is inflamed, it gets big. But in this case, the immune system was attacking the gland from the inside without making it look swollen on the outside. This is a known but rare behavior of immune attacks caused by PD-L1 drugs.

The Diagnosis
The doctors realized this was a "Grade 3" immune-related hypophysitis. In plain English, that means the immune system had severely attacked the pituitary gland, causing multi-system failure, but the damage was so hidden that standard scans couldn't see it. This was a new discovery for this specific drug, adebrelimab. While a very mild case had been seen before, this was the first time anyone had reported such a severe, delayed attack on multiple hormone systems caused by this specific medicine.

The Fix and The Aftermath
The team made a tough call: they stopped the immune drug forever. Then, they gave the patient a strong dose of steroid medicine (methylprednisolone) to calm down the angry immune system.

• The Result: The headache and dizziness went away quickly. The fatigue improved, though he still couldn't walk completely independently right away.
• The Long-Term: When they checked his blood again a month later, his stress hormone levels had improved a bit, but they were still low. His testosterone started to bounce back a little on its own. This suggests that while the "stress" part of the gland might be permanently damaged and need medicine forever, the "male hormone" part might recover on its own.

Why This Matters
This story teaches us a vital lesson. When patients take immune-boosting drugs like adebrelimab, they can get sick in very sneaky ways. The symptoms (headache, dizziness, extreme tiredness) look exactly like the cancer is getting worse or like the patient is just "burned out." But it might actually be the immune system attacking the brain's control center.

The paper suggests that doctors need to be super vigilant. They shouldn't just wait for the brain scan to show a problem, because the scan might look normal even when the gland is in trouble. Instead, they need to regularly check the blood levels of all the hormones, especially if a patient starts feeling unusually tired or dizzy after months of treatment. If they catch it early and use steroids, they can save the patient from a life-threatening crisis and help them feel better again.

The patient himself shared his experience, saying he felt like a burden to his family because he couldn't take care of himself. He hopes sharing his story will help other patients get their blood checked regularly so they don't have to suffer the same loss of independence. It's a reminder that while these drugs are powerful weapons against cancer, we have to watch out for the friendly fire.